Biopharma Executive Perspectives on 2023

Markets remain a challenge, and the Inflation Reduction Act (IRA) is messing with biopharma pipelines, but the industry’s top executives are high on the innovative potential of 2023.

BioSpace spoke with several leaders to gather their thoughts and predictions for the new year. Here is the first installment of this two-part series.